MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

101.41
+3.61
+3.69%
After Hours: 101.41 0 0.00% 17:07 09/17 EDT
OPEN
98.25
PREV CLOSE
97.80
HIGH
101.80
LOW
98.06
VOLUME
875.90K
TURNOVER
--
52 WEEK HIGH
125.59
52 WEEK LOW
64.72
MARKET CAP
9.29B
P/E (TTM)
759.63
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NBIX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NBIX News

  • Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
  • PR Newswire.10h ago
  • Neurocrine Biosciences Highlights Will Present Data On INGREZZA For Tardive Dyskinesia, Opicapone, VY-AADC For Parkinson's At International Congress of Parkinson's Disease and Movement Disorders
  • Benzinga.11h ago
  • Three Q4'19 Catalysts For Axovant
  • Seeking Alpha - Article.19h ago
  • Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors
  • PR Newswire.6d ago

More

Industry

Biotechnology & Medical Research
+0.24%
Pharmaceuticals & Medical Research
+0.57%

Hot Stocks

Name
Price
%Change

About NBIX

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
More

Webull offers Neurocrine Biosciences, Inc. (NBIX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.